A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Diabetes, Diabetes |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 8/29/2018 |
| Start Date: | February 22, 2018 |
| End Date: | June 25, 2018 |
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health
outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The
date of first exposure to the particular drug(s) in the database, where the exposure start is
between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed
and reported in this study.
outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The
date of first exposure to the particular drug(s) in the database, where the exposure start is
between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed
and reported in this study.
Inclusion Criteria:
- First exposure to the particular drug(s) in database (index date)
- Exposure start is between 1 April 2013 and 15 May 2017
- At least 365 days of continuous observation time prior to index
- At least 1 condition occurrence of 'Type II diabetes' any time in the prior continuous
observation time (which is at least 365 days long) before or on the index date (first
exposure to the particular drug(s) in database)
For cohort with 'established cardiovascular disease - At least 1 occurrence of 'conditions
indicating established cardiovascular disease' on or any time in the prior continuous
observation time (which is at least 365 days long) prior to the index date
Exclusion Criteria:
- Participants with type 1 diabetes or secondary diabetes prior to or on the index date of
exposure were excluded from the study
We found this trial at
1
site
Click here to add this to my saved trials
